Skip to main content
Vcanbio Cell & Gene Engineering Corp., Ltd logo

Vcanbio Cell & Gene Engineering Corp., Ltd — Investor Relations & Filings

Ticker · 600645 ISIN · CNE000000545 LEI · 300300FLWFDJPQYVAZ24 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,580 across all filing types
Latest filing 2019-01-27 Earnings Release
Country CN China
Listing Shanghai Stock Exchange 600645

About Vcanbio Cell & Gene Engineering Corp., Ltd

https://www.vcanbio.com/

Vcanbio Cell & Gene Engineering Corp., Ltd. specializes in the fields of cell therapy, gene technology, and precision medicine. The company operates a comprehensive business model centered on the storage of hematopoietic and mesenchymal stem cells, providing long-term bio-banking services for cord blood and other biological tissues. Its technical portfolio includes advanced genetic testing services, such as prenatal screening and oncology diagnostics, alongside the development of cell-based therapeutic products. Vcanbio maintains a network of specialized laboratories and storage facilities to support clinical research and personalized healthcare applications. The organization focuses on translating biotechnological advancements into clinical solutions, emphasizing quality control in cell processing and genomic analysis to serve the evolving needs of the regenerative medicine and diagnostic sectors.

Recent filings

Filing Released Lang Actions
2018年年度业绩预盈公告
Earnings Release Classification · 95% confidence The document is a 2018 annual performance profit forecast announcement by Zhongyuan Xiehe Cell Gene Engineering Co., Ltd. It provides estimated net profit figures for the full year 2018, including explanations of non-recurring gains and losses, and cautions about risks and uncertainties. The document explicitly states that the forecasted data is preliminary and unaudited, and that the final audited data will be disclosed in the formal 2018 annual report. The document length is short (1401 characters) and it is a forward-looking earnings forecast rather than a full financial report. This type of document is typically classified as an Earnings Release (ER) because it announces key financial results highlights for a fiscal year before the full annual report is published. FY 2018
2019-01-27 Chinese
2019年第二次临时股东大会会议资料
AGM Information Classification · 95% confidence The document is titled as materials for the "2019 Second Extraordinary General Meeting" of Zhongyuan Xiehe Cell Gene Engineering Co., Ltd. It contains detailed meeting agenda, voting procedures, and a specific proposal regarding the approval of a subsidiary's participation in a share acquisition. The content is focused on the meeting logistics, agenda, and voting, rather than financial results or detailed financial statements. The document length is 4787 characters, which is relatively short and consistent with meeting materials rather than a full report. There is no indication of financial statements or management discussion and analysis. This matches the definition of AGM Information (AGM-R), which includes presentations and materials shared during the Annual or Extraordinary General Meeting. Therefore, the document should be classified as AGM Information (AGM-R).
2019-01-23 Chinese
关于实际控制人增持公司股份计划实施结果的公告
Major Shareholding Notification Classification · 100% confidence The document is an announcement regarding the completion of a shareholding increase plan by the company's actual controller, Mr. Li Defu. It details the number of shares acquired, the cost, and the resulting ownership percentage. This type of document reports on changes in significant share ownership levels, which fits the definition of a Major Shareholding Notification (MRQ). The document is short and focused solely on shareholding changes, not a full financial report or other types of filings.
2019-01-17 Chinese
关于召开2019年第二次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed notice about the convening of the 2019 second extraordinary general meeting of shareholders (临时股东大会) for the company 中源协和细胞基因工程股份有限公司. It includes information about the meeting date, voting methods (including online voting), agenda items to be discussed, shareholder eligibility, registration procedures, and contact details. It also contains an authorization letter template for proxy voting. There is no financial data, earnings information, or audit content. The document is not a report itself but a formal announcement and notice for a shareholders' meeting. This fits the category of a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings. The document length is under 5,000 characters, but it contains substantive meeting and voting information rather than just a brief announcement, so it is not a Report Publication Announcement (RPA). Therefore, the best classification is PSI with high confidence.
2019-01-16 Chinese
关于同意子公司参与无锡产权交易所无锡傲锐东源生物科技有限公司24.14%股权摘牌的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the company's subsidiary participating in the acquisition of equity shares in another company through a property rights exchange. It details the transaction overview, parties involved, financial data of the target company, and the strategic rationale behind the acquisition. The document includes audited financial data of the target company but does not present a full financial report of the parent company or comprehensive financial statements. It is primarily a disclosure of a capital transaction involving share acquisition and equity interests. The document length is 3630 characters, which is relatively short and focused on the transaction details rather than a full report. Therefore, it fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes.
2019-01-16 Chinese
第九届董事会第二十七次会议决议公告
Board/Management Information Classification · 95% confidence The document is a board meeting resolution announcement from 中源协和细胞基因工程股份有限公司, detailing decisions made at the 27th meeting of the 9th board. It includes voting results on specific proposals and references other announcements for related matters. The content focuses on board decisions and meeting outcomes rather than financial results, audit information, or shareholder voting results. It is not a full annual or interim report, nor a call transcript or capital update. The document fits the category of Board/Management Information (MANG) as it reports on board meeting resolutions and decisions.
2019-01-16 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.